🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Recruitingn/aAges 19 Years - anyAllHK inno.N Corporation
NCT06389552 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age over 19 at the time of obtaining the informed consent form * Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery * ECOG 0 or 1 * Scheduled to RO or R1 resection * Organ function capable of chemotherapy Exclusion Criteria: * FOLFIRINOX contraindications among the drug approval requirements * Palliative Therapy * Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX
💊

What it tests

  • Not listed
📍

Where

1 site
Seoul ST. Mary's Hospital
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy